Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 28 June 2011, 15:30 HKT/SGT
Share:
    

Source: Hai Kang Life Corporation Limited
Hai Kang Life's EFADchip Technology Featured in Science Magazine

HONG KONG, June 28, 2011 - (ACN Newswire) - Hai Kang Life Corporation Limited ("Hai Kang Life"), a Hong Kong-based biotechnology company founded by professor Albert Cheung-Hoi Yu, has just received significant worldwide attention by being featured in Science magazine, the leading global scientific journal.

The Friday (June 24) issue of Science contained a full page 'News Focus on Biotechnology' article on a revolutionary new lab-on-a-chip technology that is poised to change the current clinical diagnostic paradigm, and put Hong Kong firmly on the international biotech map.

The EFADchip system developed by Hai Kang Life utilizes its propertiary patented technology to detect the presence of a pathogens genetic material in a fraction of the time and with a higher precision than existing tests. This Electric Field Assisted Diagnostic (EFAD) method is also inexpensive, allowing whole at-risk populations to be screened. For example, anyone displaying flu-like symptoms can be tested for the presence of different viruses including H1N1 or SARS. Such screening would allow for accurate disease diagnosis and thus appropriate treatment could be given to patient immediately.

In addition to infectious disease diagnosis, EFADchip can also be used for cancer detection, genetic disease testing, disease surveillance and control, as well as for non-clinical applciations such as veterinary diagnostics, environmental monitoring, testing food for microbial or GMO contamination.

The new EFADchip system comprises of chip and chip-reader ("bio-reader") that can easily be deployed to rural communities where lab facilities are unavailable. In fact, they are so small they can be installed on the office desk top of any doctor. Timely deployment of these units to disease outbreak areas could prevent the development of a global pandemic. According to Zhengping Zhuang, a clinical pathologist at the U.S. National Institutes of Health, who is not connected to Hai Kang Life, the EFADchip and the bio-reader is a unique system and it gets a readout much faster than with other technologies."

Bernard Roizman, a virologist at the University of Chicago in Illinois also comments that the EFADchip system is small in size and effectively it is a lab on a chip on wheels.


Contact:
media@haikanglife.com 


Topic: Research and development
Source: Hai Kang Life Corporation Limited

Sectors: Science & Research, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
The Moat of Full Licenses and Cross-Border Synergy - The Essence of CMBC Capital's (1141.HK) Business Competitiveness  
July 23, 2026 11:31 HKT/SGT
The Ballast Stone for Navigating Cycles: CMBC Capital (1141.HK)'s Strategic Positioning in Asset Management and Green Finance  
July 23, 2026 11:08 HKT/SGT
Leveraging the Parent Bank Ecosystem and "Commercial-Investment Banking Synergy" Advantages, CMBC Capital (1141.HK) Builds Competitive Advantage  
July 23, 2026 11:03 HKT/SGT
JCB and Fiuu Collaborate to Expand JCB Acceptance Across Southeast Asia  
Thursday, July 23, 2026 11:00:00 AM
CMBC Capital (1141.HK) Turning Point Confirmed - Operational Quality and Drivers of Improvement Behind the 2025 Annual Report  
July 23, 2026 10:58 HKT/SGT
INVEST Fair 2026 Concludes Successful Two-Day Event with Over 100 Speakers, 40 Exhibitors and over 70 Hours of Investment Insights  
July 23, 2026 09:02 HKT/SGT
Austral Gold Announces Updated Guanaco Technical Report  
July 23, 2026 08:59 HKT/SGT
CANEX to Pay Out Bulk of Dissenting Gold Basin Shareholders in Canex Shares and Updates Helix Litigation  
July 22, 2026 19:30 HKT/SGT
U.S. Polo Assn. Sponsors the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup as Official Apparel Partner  
July 22, 2026 19:00 HKT/SGT
OrbusNeich Announces Enrollment of First Patient in Japan Clinical Trial for its Proprietary Drug-Coated Balloon  
July 22, 2026 18:24 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: